RESPIRE Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)
- Coordinator
- Palo Biofarma SL, Spain
- Runs
- 1 January 2022 to 30 June 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190151672
What the project is doing
In the project's own words, from its summary on CORDIS.
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials.
With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise 30M (incl 15M EIC Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Palo Biofarma SL | Mataro | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI